JASON JAVILLO: Open Payments
NPI 1366472557 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$548 in 28 payments from 13 companies in 2025. Trend: 2023 $74 · 2024 $628 · 2025 $548
Food & beverage: $548
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $128 |
| GlaxoSmithKline, LLC. | 4 | $69 |
| Lilly USA, LLC | 4 | $68 |
| PFIZER INC. | 3 | $68 |
| ABBVIE INC. | 2 | $41 |
| Astellas Pharma US Inc | 2 | $39 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
| Gilead Sciences, Inc. | 1 | $21 |
| SANOFI-AVENTIS U.S. LLC | 1 | $21 |
Products named: Ozempic, VYNDAQEL, MOUNJARO, QULIPTA, Veozah, Rybelsus, TRELEGY ELLIPTA, SHINGRIX.
Industry payments across MD — which companies pay providers there.
